What is HC Wainwright's Estimate for ESPR FY2025 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of $1.36 for the year, up from their prior estimate of $1.29. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Esperion Therapeutics' FY2026 earnings at $2.25 EPS, FY2027 earnings at $3.14 EPS and FY2028 earnings at $6.05 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts' expectations of $51.90 million.

A number of other equities research analysts have also recently commented on ESPR. StockNews.com raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Esperion Therapeutics currently has an average rating of "Hold" and a consensus price target of $8.17.

Esperion Therapeutics Price Performance

ESPR traded up $0.24 during trading on Monday, reaching $2.52. 12,050,337 shares of the company's stock were exchanged, compared to its average volume of 6,192,498. Esperion Therapeutics has a 1 year low of $0.87 and a 1 year high of $3.40. The stock has a market capitalization of $494.50 million, a P/E ratio of -3.97 and a beta of 0.96. The company's fifty day simple moving average is $1.91 and its 200-day simple moving average is $2.13.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BOKF NA acquired a new stake in Esperion Therapeutics during the 2nd quarter worth $26,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $27,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics during the 2nd quarter worth $28,000. Sivia Capital Partners LLC purchased a new position in shares of Esperion Therapeutics during the 2nd quarter worth $44,000. Finally, National Bank of Canada FI raised its holdings in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 10,225 shares during the period. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.